Research with impact

The Monash Institute of Pharmaceutical Sciences (MIPS) has three Therapeutic Program Areas (TPAs), which encourage researchers from different backgrounds to work together on specific diseases and challenges in neuroscience and mental health, cardiovascular and metabolic health, and global health. Here are some of the research stories that emerged over 2022.

Neuroscience and mental health

New Clinical Practice Guidelines for Psychotropics in aged care

CMUS led the development of new Clinical Practice Guidelines for the Appropriate Use of Psychotropic Medications in People Living with Dementia and in Residential Aged Care.

Read more about the research being undertaken in neuroscience and mental health here.

Global health

Tackling deadly ‘superbugs’

QPX9003, a novel antibiotic targeting antibiotic-resistant ‘superbugs’ and developed by researchers from the MIPS and Monash BDI has achieved an important milestone in its clinical development, with the initial Phase 1 studies of the drug delivering very promising safety and tolerability results.

MIPS drug delivery technology Glyph™ reaches new milestones

The drug delivery technology Glyph™ was developed by Professor Chris Porter and his team at MIPS, including Natalie Trevaskis, Sifei Han, Luojuan Hu, Tim Quach and Jamie Simpson.

Developing next-generation HIV antivirals

The Burnet Institute, in collaboration with MIPS, received Proof of Concept funding from BioCurate to develop next-generation HIV antivirals.

Funding for local COVID-19 antiviral therapy

The federal government’s Medical Research Future Fund invested almost $1 million in 2022 into progressing Australian research on a combination antiviral therapy to treat COVID-19.

Cardiovascular and metabolic health

World first breakthrough for obesity treatment

A team of researchers from MIPS and the ARC Centre for Cryo-EM of Membrane Proteins published breakthrough, world-first research on a new obesity treatment in the prestigious journal Science in early 2022.

Nitroxyl represents a promising therapeutic intervention for cardiovascular emergencies in type 2 diabetes

Monash University researchers led a study that has, for the first time, shown the chemical compound 'nitroxyl' may represent an effective and rapid intervention for cardiovascular emergencies in type 2 diabetes mellitus.

Return to Issue 35

Return to issue homepage.

Made at MIPS

Recent commercialisation successes

Making waves in mRNA

Monash made a name for itself in the global race to find a vaccine against COVID-19. The University remains at the forefront of mRNA research in Australia.